[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]

Area of Science:

• Pharmacology
• Drug Safety
• Clinical Medicine

Background:

• The HMG-CoA-reductase inhibitor cerivastatin was withdrawn globally in 2001 due to fatal rhabdomyolysis.
• This event raised safety concerns for the entire statin class, despite cerivastatin's higher incidence of severe side effects compared to other statins.

Purpose of the Study:

• To investigate the specific pharmacokinetic and pharmacodynamic characteristics of cerivastatin that led to its high frequency of fatal rhabdomyolysis.
• To differentiate the safety profile of cerivastatin from other statins.

Main Methods:

• Comparative analysis of pharmacokinetic properties (e.g., oral bioavailability, drug interactions) among statins.
• Evaluation of pharmacodynamic properties, specifically the IC50 for HMG-CoA-reductase inhibition.
• Assessment of potential mechanisms leading to skeletal muscle cell apoptosis and energy depletion.

Main Results:

• Cerivastatin exhibits the highest oral bioavailability and lowest IC50 for HMG-CoA-reductase inhibition within its class.
• Drug interactions, such as with gemfibrocil, can further elevate cerivastatin plasma levels.
• These factors contribute to apoptosis and energy depletion in skeletal muscle cells.

Conclusions:

• Fatal rhabdomyolysis associated with cerivastatin is attributed to its specific pharmacokinetic and pharmacodynamic profile, not a class-wide issue.
• The findings underscore the importance of ongoing clinical studies and precise adverse event reporting for all medications, including established ones.